Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Choriogonadotropin alfa + epoetin alfa** is a combination of two recombinant protein biologics: choriogonadotropin alfa and epoetin alfa.\n- **Choriogonadotropin alfa** is a recombinant form of human chorionic gonadotropin (hCG) used primarily to induce ovulation in female infertility. It acts as a luteinizing hormone receptor agonist to stimulate ovulation, luteinization, and steroid production in the ovaries, mimicking the physiologic actions of endogenous hCG[3].\n- **Epoetin alfa** is a recombinant human erythropoietin analog that stimulates erythropoiesis (red blood cell production) by acting on the erythropoietin receptor in bone marrow, primarily used to treat anemia associated with chronic kidney disease, myelosuppressive chemotherapy, and certain other conditions[2][4].\nThere is no evidence of a marketed or clinically tested combination product of these two biologics as a fixed co-formulation. Therefore, this refers to concomitant use of these two agents, most likely in a research, fertility, or supportive care setting, but not as a single, branded pharmaceutical entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on choriogonadotropin alfa + epoetin alfa.